Global Anxiety Disorder and Depression Treatment Market: Industry Analysis and forecast (2022-2029)

Anxiety Disorder and Depression Treatment Market is expected to reach US$ 13.71 Bn. at a CAGR of 2.6% during the forecast period 2029. Depression affects 350 million people globally and takes over one million lives through suicide each year, making it the largest cause of disability. The burden of MDD in the Asia-Pacific region is around 3.1% of the total, which is greater than the global average but remains under-represented due to sample and reporting difficulties. The social and economic repercussions are overwhelming, yet efforts to counteract the growing tide of Major Depression are failing - there are still stigmas that make people afraid to seek assistance, inefficient diagnostic and treatment procedures, and patient routes that are difficult to navigate. Location is an important contextual aspect of the industry, particularly in the Asia-Pacific region. Remote areas have poorer socioeconomic status, and studies suggest that the higher the prevalence of serious mental illness, the higher the rate of poverty. However, in these locations where assistance is most needed, support networks for Depression are limited, and awareness of the illness spectrum is inadequate. It is not rare to find 70 or more psychiatrists per 100,000 persons in metropolitan areas, whereas less in rural areas. To put it bluntly, the rate of psychiatrists in high-income countries is 170 times that of LMICs. There is a strong link between socioeconomic level, depression attitudes, and the availability of assistance. Novel methods to overcome the urban-rural gap are emerging, particularly via the use of technology. Depression has an immediate impact on labor productivity, economic prospects, and society as a whole. For example, in China Mainland, DALYs (Disability-Adjusted Life Years) attributable to mental diseases increased from 7% to 11%; in India, the same figures increased from 3% to 6%. The economic worth of such DALYs is about USD 10 trillion, with up to 55% manifesting in endpoints like suicide and loss of labor force production. The market is segmented based on Drug Class, Therapies, Application, and Region. The growth of various segments helps the report users in acquiring knowledge of the many growth factors expected to be prevalent throughout the market and develop different strategies to help identify core application areas and the gap in the target market. The report provides an in-depth analysis of the market and contains meaningful insights, facts, historical data, and statistically supported and industry-validated market statistics. Anxiety Disorder and Depression Treatment Market To know about the Research Methodology:-Request Free Sample Report

Global Anxiety Disorder and Depression Treatment Market Drivers and Restrains

Increasing prevalence of mental health issues and disorders like anxiety disorder and depression followed by rising demand for antidepressants due to minimum side effects associated with these medications and growing awareness levels amongst the consumers are the factors fueling the growth of Global Anxiety Disorder and Depression Treatment Market during forecast period. The growing population with mental issues like Alzheimer's, trauma, is also acting as a driving factor for the global Anxiety Disorder and Depression Treatment Market. The high cost associated with the use of these devices and therapies including anesthesia and hospital stay has hampered the growth of global Anxiety Disorder and Depression Treatment Market

Global Anxiety Disorder and Depression Treatment Market Segment Analysis

Global Anxiety Disorder and Depression Treatment Market is segmented by Drug class, Therapies, Application. By Drug class selective Serotonin Reuptake Inhibitors (SSRIs), Antidepressant Drugs, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Benzodiazepines, Atypical Antipsychotics, Anticonvulsants, Beta-Blockers and Others. Among these, Selective Serotonin Reuptake Inhibitors (SSRIs) segment is expected to hold significant share of Global Anxiety Disorder and Depression Treatment Market. SSRIs relieve symptoms by blocking the reabsorption, or reuptake, of serotonin by certain nerve cells in the brain. This leaves more serotonin available, which improves mood. SSRIs (citalopram, escitalopram, fluoxetine, paroxetine, and sertraline) generally produced fewer which is a side effects, when compared with tricyclic antidepressants. By Therapies Electroconvulsive Therapy (ECT), Cognitive Behavior Therapy (CBT), Psychotherapy, Deep Brain Stimulation, Transcranial Magnetic Stimulation (TMS), Cranial electrotherapy stimulation (CES). Anxiety Disorder and Depression Treatment Market

Global Anxiety Disorder and Depression Treatment Market Regional Insights

Global Anxiety Disorder and Depression Treatment Market by region is segmented into Asia Pacific, North America, Europe, Latin America and Middle East Africa. Among these North America is expected to hold largest share of global Anxiety Disorder and Depression Treatment Market. Supportive government policies, availability of different branded formulations, and higher awareness levels are responsible for this increased growth rate in this region. Another mentionable factor contributing to market share being held by North America is the easy accessibility of the antidepressant market. Asia pacific expected to grow with lucrative CAGR of xx% during forecast period owing to increasing disposable income of individuals and large demand for antidepressants stemming from the high prevalence of anxiety disorders.

Global Anxiety Disorder and Depression Treatment Market Scope: Inquire before buying

Global Anxiety Disorder and Depression Treatment Market, by Drug class

• selective Serotonin Reuptake Inhibitors (SSRIs) • Antidepressant Drugs • Tricyclic Antidepressants (TCAs) • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) • Monoamine Oxidase Inhibitors (MAOIs) • Benzodiazepines • Atypical Antipsychotics • Anticonvulsants • Beta-Blockers • Others

Global Anxiety Disorder and Depression Treatment Market, by Therapies

• Electroconvulsive Therapy (ECT) • Cognitive Behavior Therapy (CBT) • Psychotherapy • Deep Brain Stimulation • Transcranial Magnetic Stimulation (TMS) • Cranial electrotherapy stimulation (CES)

Global Anxiety Disorder and Depression Treatment Market, by Application

• Phobia • Major Depressive Disorder • Obsessive Compulsive Disorder (OCD) • Post-traumatic stress disorder • Others

Global Anxiety Disorder and Depression Treatment Market, by Region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Global Anxiety Disorder and Depression Treatment Market Key Players

• Eli Lilly and Company, • Forest Laboratories, Inc., • AstraZeneca PLC, • Sanofi-Aventis, • Merck & Co., Inc., • Pfizer, Inc., • GlaxoSmithKline plc. • Johnson & Johnson • H. Lund beck A/S, • Forest Laboratories, Inc., • Sanofi-Aventis • Bristol-Myers Squibb Company • Novartis AG • Mylan N.V • Glenmark Life Sciences Limited • Lupin Limited • Amneal Pharmaceuticals Inc. • Sun Pharmaceutical Industries Ltd. • Sumitomo Dainippon Pharma Co. Ltd. • Intas Pharmaceuticals Ltd. Frequently Asked Questions: 1. Which region has the largest share in Global Anxiety Disorder and Depression Treatment Market? Ans: North America region held the highest share in 2021. 2. What is the growth rate of Global Anxiety Disorder and Depression Treatment Market? Ans: The Global Anxiety Disorder and Depression Treatment Market is growing at a CAGR of 2.6% during forecasting period 2022-2029. 3. What is scope of the Global Anxiety Disorder and Depression Treatment market report? Ans: Global Anxiety Disorder and Depression Treatment Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Anxiety Disorder and Depression Treatment market? Ans: The important key players in the Global Anxiety Disorder and Depression Treatment Market are – Eli Lilly and Company,, Forest Laboratories, Inc.,, AstraZeneca PLC,, Sanofi-Aventis,, Merck & Co., Inc.,, Pfizer, Inc.,, GlaxoSmithKline plc., Johnson & Johnson, H. Lund beck A/S,, Forest Laboratories, Inc.,, Sanofi-Aventis, Bristol-Myers Squibb Company, Novartis AG, Mylan N.V, Glenmark Life Sciences Limited, Lupin Limited, Amneal Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., and Intas Pharmaceuticals Ltd. 5. What is the study period of this market? Ans: The Global Anxiety Disorder and Depression Treatment Market is studied from 2022 to 2029.
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Anxiety Disorder and Depression Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Anxiety Disorder and Depression Treatment Market Analysis and Forecast 6.1. Global Anxiety Disorder and Depression Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Anxiety Disorder and Depression Treatment Market Analysis and Forecast, by Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 7.4. Global Anxiety Disorder and Depression Treatment Market Size (US$ Bn) Forecast, by Application 7.5. Global Anxiety Disorder and Depression Treatment Market Analysis, by Application 7.6. Global Anxiety Disorder and Depression Treatment Market Attractiveness Analysis, by Application 8. Global Anxiety Disorder and Depression Treatment Market Analysis and Forecast, by Drug class 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 8.4. Global Anxiety Disorder and Depression Treatment Market Size (US$ Bn) Forecast, by Drug class 8.5. Global Anxiety Disorder and Depression Treatment Market Analysis, by Drug class 8.6. Global Anxiety Disorder and Depression Treatment Market Attractiveness Analysis, by Drug class 9. Global Anxiety Disorder and Depression Treatment Market Analysis and Forecast, by Therapies 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 9.4. Global Anxiety Disorder and Depression Treatment Market Size (US$ Bn) Forecast, by Therapies 9.5. Global Anxiety Disorder and Depression Treatment Market Analysis, by Therapies 9.6. Global Anxiety Disorder and Depression Treatment Market Attractiveness Analysis, by Therapies 10. Global Anxiety Disorder and Depression Treatment Market Analysis, by Region 10.1. Global Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Region 10.2. Global Anxiety Disorder and Depression Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Global Anxiety Disorder and Depression Treatment Market Attractiveness Analysis, by Region 11. North America Anxiety Disorder and Depression Treatment Market Analysis 11.1. Key Findings 11.2. North America Anxiety Disorder and Depression Treatment Market Overview 11.3. North America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 11.4. North America Anxiety Disorder and Depression Treatment Market Forecast, by Application 11.4.1. Phobia 11.4.2. Major Depressive Disorder 11.4.3. Obsessive Compulsive Disorder (OCD) 11.4.4. Post-traumatic stress disorder 11.4.5. Others 11.5. North America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 11.6. North America Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 11.6.1. selective Serotonin Reuptake Inhibitors (SSRIs) 11.6.2. Antidepressant Drugs 11.6.3. Tricyclic Antidepressants (TCAs) 11.6.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 11.6.5. Monoamine Oxidase Inhibitors (MAOIs) 11.6.6. Benzodiazepines 11.6.7. Atypical Antipsychotics 11.6.8. Anticonvulsants 11.6.9. Beta-Blockers 11.6.10. Others 11.7. North America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 11.8. North America Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 11.8.1. Electroconvulsive Therapy (ECT) 11.8.2. Cognitive Behavior Therapy (CBT) 11.8.3. Psychotherapy 11.8.4. Deep Brain Stimulation 11.8.5. Transcranial Magnetic Stimulation (TMS) 11.8.6. Cranial electrotherapy stimulation (CES) 11.9. North America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Country 11.10. North America Anxiety Disorder and Depression Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Anxiety Disorder and Depression Treatment Market Analysis, by Country 11.12. U.S. Anxiety Disorder and Depression Treatment Market Forecast, by Application 11.12.1. Phobia 11.12.2. Major Depressive Disorder 11.12.3. Obsessive Compulsive Disorder (OCD) 11.12.4. Post-traumatic stress disorder 11.12.5. Others  11.13. U.S. Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 11.13.1. selective Serotonin Reuptake Inhibitors (SSRIs) 11.13.2. Antidepressant Drugs 11.13.3. Tricyclic Antidepressants (TCAs) 11.13.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 11.13.5. Monoamine Oxidase Inhibitors (MAOIs) 11.13.6. Benzodiazepines 11.13.7. Atypical Antipsychotics 11.13.8. Anticonvulsants 11.13.9. Beta-Blockers 11.13.10. Others 11.14. U.S. Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 11.14.1. Electroconvulsive Therapy (ECT) 11.14.2. Cognitive Behavior Therapy (CBT) 11.14.3. Psychotherapy 11.14.4. Deep Brain Stimulation 11.14.5. Transcranial Magnetic Stimulation (TMS) 11.14.6. Cranial electrotherapy stimulation (CES) 11.15. Canada Anxiety Disorder and Depression Treatment Market Forecast, by Application 11.15.1. Phobia 11.15.2. Major Depressive Disorder 11.15.3. Obsessive Compulsive Disorder (OCD) 11.15.4. Post-traumatic stress disorder 11.15.5. Others 11.16. Steel Canada Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 11.16.1. selective Serotonin Reuptake Inhibitors (SSRIs) 11.16.2. Antidepressant Drugs 11.16.3. Tricyclic Antidepressants (TCAs) 11.16.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 11.16.5. Monoamine Oxidase Inhibitors (MAOIs) 11.16.6. Benzodiazepines 11.16.7. Atypical Antipsychotics 11.16.8. Anticonvulsants 11.16.9. Beta-Blockers 11.16.10. Others 11.17. Canada Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 11.17.1. Electroconvulsive Therapy (ECT) 11.17.2. Cognitive Behavior Therapy (CBT) 11.17.3. Psychotherapy 11.17.4. Deep Brain Stimulation 11.17.5. Transcranial Magnetic Stimulation (TMS) 11.17.6. Cranial electrotherapy stimulation (CES) 11.18. North America Anxiety Disorder and Depression Treatment Market Attractiveness Analysis 11.18.1. By Application 11.18.2. By Drug class 11.18.3. By Therapies 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Anxiety Disorder and Depression Treatment Market Analysis 12.1. Key Findings 12.2. Europe Anxiety Disorder and Depression Treatment Market Overview 12.3. Europe Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 12.4. Europe Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.4.1. Phobia 12.4.2. Major Depressive Disorder 12.4.3. Obsessive Compulsive Disorder (OCD) 12.4.4. Post-traumatic stress disorder 12.4.5. Others 12.5. Europe Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 12.6. Europe Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.6.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.6.2. Antidepressant Drugs 12.6.3. Tricyclic Antidepressants (TCAs) 12.6.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.6.5. Monoamine Oxidase Inhibitors (MAOIs) 12.6.6. Benzodiazepines 12.6.7. Atypical Antipsychotics 12.6.8. Anticonvulsants 12.6.9. Beta-Blockers 12.6.10. Others 12.7. Europe Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 12.8. Europe Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.8.1. Electroconvulsive Therapy (ECT) 12.8.2. Cognitive Behavior Therapy (CBT) 12.8.3. Psychotherapy 12.8.4. Deep Brain Stimulation 12.8.5. Transcranial Magnetic Stimulation (TMS) 12.8.6. Cranial electrotherapy stimulation (CES) 12.9. Europe Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Country 12.10. Europe Anxiety Disorder and Depression Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Anxiety Disorder and Depression Treatment Market Analysis, by Country 12.12. Germany Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.12.1. Phobia 12.12.2. Major Depressive Disorder 12.12.3. Obsessive Compulsive Disorder (OCD) 12.12.4. Post-traumatic stress disorder 12.12.5. Others 12.13. Germany Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.13.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.13.2. Antidepressant Drugs 12.13.3. Tricyclic Antidepressants (TCAs) 12.13.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.13.5. Monoamine Oxidase Inhibitors (MAOIs) 12.13.6. Benzodiazepines 12.13.7. Atypical Antipsychotics 12.13.8. Anticonvulsants 12.13.9. Beta-Blockers 12.13.10. Others 12.14. Germany Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.14.1. Electroconvulsive Therapy (ECT) 12.14.2. Cognitive Behavior Therapy (CBT) 12.14.3. Psychotherapy 12.14.4. Deep Brain Stimulation 12.14.5. Transcranial Magnetic Stimulation (TMS) 12.14.6. Cranial electrotherapy stimulation (CES) 12.15. U.K. Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.15.1. Phobia 12.15.2. Major Depressive Disorder 12.15.3. Obsessive Compulsive Disorder (OCD) 12.15.4. Post-traumatic stress disorder 12.15.5. Others 12.16. U.K. Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.16.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.16.2. Antidepressant Drugs 12.16.3. Tricyclic Antidepressants (TCAs) 12.16.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.16.5. Monoamine Oxidase Inhibitors (MAOIs) 12.16.6. Benzodiazepines 12.16.7. Atypical Antipsychotics 12.16.8. Anticonvulsants 12.16.9. Beta-Blockers 12.16.10. Others 12.17. U.K. Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.17.1. Electroconvulsive Therapy (ECT) 12.17.2. Cognitive Behavior Therapy (CBT) 12.17.3. Psychotherapy 12.17.4. Deep Brain Stimulation 12.17.5. Transcranial Magnetic Stimulation (TMS) 12.17.6. Cranial electrotherapy stimulation (CES) 12.18. France Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.18.1. Phobia 12.18.2. Major Depressive Disorder 12.18.3. Obsessive Compulsive Disorder (OCD) 12.18.4. Post-traumatic stress disorder 12.18.5. Others 12.19. France Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.19.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.19.2. Antidepressant Drugs 12.19.3. Tricyclic Antidepressants (TCAs) 12.19.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.19.5. Monoamine Oxidase Inhibitors (MAOIs) 12.19.6. Benzodiazepines 12.19.7. Atypical Antipsychotics 12.19.8. Anticonvulsants 12.19.9. Beta-Blockers 12.19.10. Others 12.20. France Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.20.1. Electroconvulsive Therapy (ECT) 12.20.2. Cognitive Behavior Therapy (CBT) 12.20.3. Psychotherapy 12.20.4. Deep Brain Stimulation 12.20.5. Transcranial Magnetic Stimulation (TMS) 12.20.6. Cranial electrotherapy stimulation (CES) 12.21. Italy Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.21.1. Phobia 12.21.2. Major Depressive Disorder 12.21.3. Obsessive Compulsive Disorder (OCD) 12.21.4. Post-traumatic stress disorder 12.21.5. Others 12.22. Italy Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.22.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.22.2. Antidepressant Drugs 12.22.3. Tricyclic Antidepressants (TCAs) 12.22.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.22.5. Monoamine Oxidase Inhibitors (MAOIs) 12.22.6. Benzodiazepines 12.22.7. Atypical Antipsychotics 12.22.8. Anticonvulsants 12.22.9. Beta-Blockers 12.22.10. Others 12.23. Italy Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.23.1. Electroconvulsive Therapy (ECT) 12.23.2. Cognitive Behavior Therapy (CBT) 12.23.3. Psychotherapy 12.23.4. Deep Brain Stimulation 12.23.5. Transcranial Magnetic Stimulation (TMS) 12.23.6. Cranial electrotherapy stimulation (CES) 12.24. Spain Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.24.1. Phobia 12.24.2. Major Depressive Disorder 12.24.3. Obsessive Compulsive Disorder (OCD) 12.24.4. Post-traumatic stress disorder 12.24.5. Others 12.25. Spain Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.25.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.25.2. Antidepressant Drugs 12.25.3. Tricyclic Antidepressants (TCAs) 12.25.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.25.5. Monoamine Oxidase Inhibitors (MAOIs) 12.25.6. Benzodiazepines 12.25.7. Atypical Antipsychotics 12.25.8. Anticonvulsants 12.25.9. Beta-Blockers 12.25.10. Others 12.26. Spain Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.26.1. Electroconvulsive Therapy (ECT) 12.26.2. Cognitive Behavior Therapy (CBT) 12.26.3. Psychotherapy 12.26.4. Deep Brain Stimulation 12.26.5. Transcranial Magnetic Stimulation (TMS) 12.26.6. Cranial electrotherapy stimulation (CES) 12.27. Rest of Europe Anxiety Disorder and Depression Treatment Market Forecast, by Application 12.27.1. Phobia 12.27.2. Major Depressive Disorder 12.27.3. Obsessive Compulsive Disorder (OCD) 12.27.4. Post-traumatic stress disorder 12.27.5. Others 12.28. Rest of Europe Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 12.28.1. selective Serotonin Reuptake Inhibitors (SSRIs) 12.28.2. Antidepressant Drugs 12.28.3. Tricyclic Antidepressants (TCAs) 12.28.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 12.28.5. Monoamine Oxidase Inhibitors (MAOIs) 12.28.6. Benzodiazepines 12.28.7. Atypical Antipsychotics 12.28.8. Anticonvulsants 12.28.9. Beta-Blockers 12.28.10. Others 12.29. Rest Of Europe Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 12.29.1. Electroconvulsive Therapy (ECT) 12.29.2. Cognitive Behavior Therapy (CBT) 12.29.3. Psychotherapy 12.29.4. Deep Brain Stimulation 12.29.5. Transcranial Magnetic Stimulation (TMS) 12.29.6. Cranial electrotherapy stimulation (CES) 12.30. Europe Anxiety Disorder and Depression Treatment Market Attractiveness Analysis 12.30.1. By Application 12.30.2. By Drug class 12.30.3. By Therapies 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Anxiety Disorder and Depression Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Anxiety Disorder and Depression Treatment Market Overview 13.3. Asia Pacific Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 13.4. Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.4.1. Phobia 13.4.2. Major Depressive Disorder 13.4.3. Obsessive Compulsive Disorder (OCD) 13.4.4. Post-traumatic stress disorder 13.4.5. Others 13.5. Asia Pacific Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 13.6. Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.6.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.6.2. Antidepressant Drugs 13.6.3. Tricyclic Antidepressants (TCAs) 13.6.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.6.5. Monoamine Oxidase Inhibitors (MAOIs) 13.6.6. Benzodiazepines 13.6.7. Atypical Antipsychotics 13.6.8. Anticonvulsants 13.6.9. Beta-Blockers 13.6.10. Others 13.7. Asia Pacific Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 13.8. Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.8.1. Electroconvulsive Therapy (ECT) 13.8.2. Cognitive Behavior Therapy (CBT) 13.8.3. Psychotherapy 13.8.4. Deep Brain Stimulation 13.8.5. Transcranial Magnetic Stimulation (TMS) 13.8.6. Cranial electrotherapy stimulation (CES) 13.9. Asia Pacific Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Anxiety Disorder and Depression Treatment Market Analysis, by Country 13.12. China Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.12.1. Phobia 13.12.2. Major Depressive Disorder 13.12.3. Obsessive Compulsive Disorder (OCD) 13.12.4. Post-traumatic stress disorder 13.12.5. Others 13.13. China Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.13.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.13.2. Antidepressant Drugs 13.13.3. Tricyclic Antidepressants (TCAs) 13.13.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.13.5. Monoamine Oxidase Inhibitors (MAOIs) 13.13.6. Benzodiazepines 13.13.7. Atypical Antipsychotics 13.13.8. Anticonvulsants 13.13.9. Beta-Blockers 13.13.10. Others 13.14. China Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.14.1. Electroconvulsive Therapy (ECT) 13.14.2. Cognitive Behavior Therapy (CBT) 13.14.3. Psychotherapy 13.14.4. Deep Brain Stimulation 13.14.5. Transcranial Magnetic Stimulation (TMS) 13.14.6. Cranial electrotherapy stimulation (CES) 13.15. India Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.15.1. Phobia 13.15.2. Major Depressive Disorder 13.15.3. Obsessive Compulsive Disorder (OCD) 13.15.4. Post-traumatic stress disorder 13.15.5. Others 13.16. India Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.16.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.16.2. Antidepressant Drugs 13.16.3. Tricyclic Antidepressants (TCAs) 13.16.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.16.5. Monoamine Oxidase Inhibitors (MAOIs) 13.16.6. Benzodiazepines 13.16.7. Atypical Antipsychotics 13.16.8. Anticonvulsants 13.16.9. Beta-Blockers 13.16.10. Others 13.17. India Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.17.1. Electroconvulsive Therapy (ECT) 13.17.2. Cognitive Behavior Therapy (CBT) 13.17.3. Psychotherapy 13.17.4. Deep Brain Stimulation 13.17.5. Transcranial Magnetic Stimulation (TMS) 13.17.6. Cranial electrotherapy stimulation (CES) 13.18. Japan Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.18.1. Phobia 13.18.2. Major Depressive Disorder 13.18.3. Obsessive Compulsive Disorder (OCD) 13.18.4. Post-traumatic stress disorder 13.18.5. Others 13.19. Japan Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.19.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.19.2. Antidepressant Drugs 13.19.3. Tricyclic Antidepressants (TCAs) 13.19.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.19.5. Monoamine Oxidase Inhibitors (MAOIs) 13.19.6. Benzodiazepines 13.19.7. Atypical Antipsychotics 13.19.8. Anticonvulsants 13.19.9. Beta-Blockers 13.19.10. Others 13.20. Japan Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.20.1. Electroconvulsive Therapy (ECT) 13.20.2. Cognitive Behavior Therapy (CBT) 13.20.3. Psychotherapy 13.20.4. Deep Brain Stimulation 13.20.5. Transcranial Magnetic Stimulation (TMS) 13.20.6. Cranial electrotherapy stimulation (CES) 13.21. ASEAN Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.21.1. Phobia 13.21.2. Major Depressive Disorder 13.21.3. Obsessive Compulsive Disorder (OCD) 13.21.4. Post-traumatic stress disorder 13.21.5. Others 13.22. ASEAN Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.22.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.22.2. Antidepressant Drugs 13.22.3. Tricyclic Antidepressants (TCAs) 13.22.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.22.5. Monoamine Oxidase Inhibitors (MAOIs) 13.22.6. Benzodiazepines 13.22.7. Atypical Antipsychotics 13.22.8. Anticonvulsants 13.22.9. Beta-Blockers 13.22.10. Others 13.23. ASEAN Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.23.1. Electroconvulsive Therapy (ECT) 13.23.2. Cognitive Behavior Therapy (CBT) 13.23.3. Psychotherapy 13.23.4. Deep Brain Stimulation 13.23.5. Transcranial Magnetic Stimulation (TMS) 13.23.6. Cranial electrotherapy stimulation (CES) 13.24. Rest of Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Application 13.24.1. Phobia 13.24.2. Major Depressive Disorder 13.24.3. Obsessive Compulsive Disorder (OCD) 13.24.4. Post-traumatic stress disorder 13.24.5. Others 13.25. Rest of Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 13.25.1. selective Serotonin Reuptake Inhibitors (SSRIs) 13.25.2. Antidepressant Drugs 13.25.3. Tricyclic Antidepressants (TCAs) 13.25.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 13.25.5. Monoamine Oxidase Inhibitors (MAOIs) 13.25.6. Benzodiazepines 13.25.7. Atypical Antipsychotics 13.25.8. Anticonvulsants 13.25.9. Beta-Blockers 13.25.10. Others 13.26. Rest of Asia Pacific Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 13.26.1. Electroconvulsive Therapy (ECT) 13.26.2. Cognitive Behavior Therapy (CBT) 13.26.3. Psychotherapy 13.26.4. Deep Brain Stimulation 13.26.5. Transcranial Magnetic Stimulation (TMS) 13.26.6. Cranial electrotherapy stimulation (CES) 13.27. Asia Pacific Anxiety Disorder and Depression Treatment Market Attractiveness Analysis 13.27.1. By Application 13.27.2. By Drug class 13.27.3. By Therapies 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Anxiety Disorder and Depression Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Anxiety Disorder and Depression Treatment Market Overview 14.3. Middle East & Africa Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 14.4. Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Application 14.4.1. Phobia 14.4.2. Major Depressive Disorder 14.4.3. Obsessive Compulsive Disorder (OCD) 14.4.4. Post-traumatic stress disorder 14.4.5. Others 14.5. Middle East & Africa Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 14.6. Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 14.6.1. selective Serotonin Reuptake Inhibitors (SSRIs) 14.6.2. Antidepressant Drugs 14.6.3. Tricyclic Antidepressants (TCAs) 14.6.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 14.6.5. Monoamine Oxidase Inhibitors (MAOIs) 14.6.6. Benzodiazepines 14.6.7. Atypical Antipsychotics 14.6.8. Anticonvulsants 14.6.9. Beta-Blockers 14.6.10. Others 14.7. Middle East & Africa Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 14.8. Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 14.8.1. Electroconvulsive Therapy (ECT) 14.8.2. Cognitive Behavior Therapy (CBT) 14.8.3. Psychotherapy 14.8.4. Deep Brain Stimulation 14.8.5. Transcranial Magnetic Stimulation (TMS) 14.8.6. Cranial electrotherapy stimulation (CES) 14.9. Middle East & Africa Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Anxiety Disorder and Depression Treatment Market Analysis, by Country 14.12. GCC Anxiety Disorder and Depression Treatment Market Forecast, by Application 14.12.1. Phobia 14.12.2. Major Depressive Disorder 14.12.3. Obsessive Compulsive Disorder (OCD) 14.12.4. Post-traumatic stress disorder 14.12.5. Others 14.13. GCC Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 14.13.1. selective Serotonin Reuptake Inhibitors (SSRIs) 14.13.2. Antidepressant Drugs 14.13.3. Tricyclic Antidepressants (TCAs) 14.13.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 14.13.5. Monoamine Oxidase Inhibitors (MAOIs) 14.13.6. Benzodiazepines 14.13.7. Atypical Antipsychotics 14.13.8. Anticonvulsants 14.13.9. Beta-Blockers 14.13.10. Others 14.14. GCC Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 14.14.1. Electroconvulsive Therapy (ECT) 14.14.2. Cognitive Behavior Therapy (CBT) 14.14.3. Psychotherapy 14.14.4. Deep Brain Stimulation 14.14.5. Transcranial Magnetic Stimulation (TMS) 14.14.6. Cranial electrotherapy stimulation (CES) 14.15. South Africa Anxiety Disorder and Depression Treatment Market Forecast, by Application 14.15.1. Phobia 14.15.2. Major Depressive Disorder 14.15.3. Obsessive Compulsive Disorder (OCD) 14.15.4. Post-traumatic stress disorder 14.15.5. Others 14.16. South Africa Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 14.16.1. selective Serotonin Reuptake Inhibitors (SSRIs) 14.16.2. Antidepressant Drugs 14.16.3. Tricyclic Antidepressants (TCAs) 14.16.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 14.16.5. Monoamine Oxidase Inhibitors (MAOIs) 14.16.6. Benzodiazepines 14.16.7. Atypical Antipsychotics 14.16.8. Anticonvulsants 14.16.9. Beta-Blockers 14.16.10. Others 14.17. South Africa Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 14.17.1. Electroconvulsive Therapy (ECT) 14.17.2. Cognitive Behavior Therapy (CBT) 14.17.3. Psychotherapy 14.17.4. Deep Brain Stimulation 14.17.5. Transcranial Magnetic Stimulation (TMS) 14.17.6. Cranial electrotherapy stimulation (CES) 14.18. Rest of Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Application 14.18.1. Phobia 14.18.2. Major Depressive Disorder 14.18.3. Obsessive Compulsive Disorder (OCD) 14.18.4. Post-traumatic stress disorder 14.18.5. Others 14.19. Rest of Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 14.19.1. selective Serotonin Reuptake Inhibitors (SSRIs) 14.19.2. Antidepressant Drugs 14.19.3. Tricyclic Antidepressants (TCAs) 14.19.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 14.19.5. Monoamine Oxidase Inhibitors (MAOIs) 14.19.6. Benzodiazepines 14.19.7. Atypical Antipsychotics 14.19.8. Anticonvulsants 14.19.9. Beta-Blockers 14.19.10. Others 14.20. Rest of Middle East & Africa Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 14.20.1. Electroconvulsive Therapy (ECT) 14.20.2. Cognitive Behavior Therapy (CBT) 14.20.3. Psychotherapy 14.20.4. Deep Brain Stimulation 14.20.5. Transcranial Magnetic Stimulation (TMS) 14.20.6. Cranial electrotherapy stimulation (CES) 14.21. Middle East & Africa Anxiety Disorder and Depression Treatment Market Attractiveness Analysis 14.21.1. By Application 14.21.2. By Drug class 14.21.3. By Therapies 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Anxiety Disorder and Depression Treatment Market Analysis 15.1. Key Findings 15.2. South America Anxiety Disorder and Depression Treatment Market Overview 15.3. South America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Application 15.4. South America Anxiety Disorder and Depression Treatment Market Forecast, by Application 15.4.1. Phobia 15.4.2. Major Depressive Disorder 15.4.3. Obsessive Compulsive Disorder (OCD) 15.4.4. Post-traumatic stress disorder 15.4.5. Others 15.5. South America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Drug class 15.6. South America Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 15.6.1. selective Serotonin Reuptake Inhibitors (SSRIs) 15.6.2. Antidepressant Drugs 15.6.3. Tricyclic Antidepressants (TCAs) 15.6.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 15.6.5. Monoamine Oxidase Inhibitors (MAOIs) 15.6.6. Benzodiazepines 15.6.7. Atypical Antipsychotics 15.6.8. Anticonvulsants 15.6.9. Beta-Blockers 15.6.10. Others 15.7. South America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Therapies 15.8. South America Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 15.8.1. Electroconvulsive Therapy (ECT) 15.8.2. Cognitive Behavior Therapy (CBT) 15.8.3. Psychotherapy 15.8.4. Deep Brain Stimulation 15.8.5. Transcranial Magnetic Stimulation (TMS) 15.8.6. Cranial electrotherapy stimulation (CES) 15.9. South America Anxiety Disorder and Depression Treatment Market Value Share Analysis, by Country 15.10. South America Anxiety Disorder and Depression Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Anxiety Disorder and Depression Treatment Market Analysis, by Country 15.12. Brazil Anxiety Disorder and Depression Treatment Market Forecast, by Application 15.12.1. Phobia 15.12.2. Major Depressive Disorder 15.12.3. Obsessive Compulsive Disorder (OCD) 15.12.4. Post-traumatic stress disorder 15.12.5. Others 15.13. Brazil Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 15.13.1. selective Serotonin Reuptake Inhibitors (SSRIs) 15.13.2. Antidepressant Drugs 15.13.3. Tricyclic Antidepressants (TCAs) 15.13.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 15.13.5. Monoamine Oxidase Inhibitors (MAOIs) 15.13.6. Benzodiazepines 15.13.7. Atypical Antipsychotics 15.13.8. Anticonvulsants 15.13.9. Beta-Blockers 15.13.10. Others 15.14. Brazil Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 15.14.1. Electroconvulsive Therapy (ECT) 15.14.2. Cognitive Behavior Therapy (CBT) 15.14.3. Psychotherapy 15.14.4. Deep Brain Stimulation 15.14.5. Transcranial Magnetic Stimulation (TMS) 15.14.6. Cranial electrotherapy stimulation (CES) 15.15. Mexico Anxiety Disorder and Depression Treatment Market Forecast, by Application 15.15.1. Phobia 15.15.2. Major Depressive Disorder 15.15.3. Obsessive Compulsive Disorder (OCD) 15.15.4. Post-traumatic stress disorder 15.15.5. Others 15.16. Mexico Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 15.16.1. selective Serotonin Reuptake Inhibitors (SSRIs) 15.16.2. Antidepressant Drugs 15.16.3. Tricyclic Antidepressants (TCAs) 15.16.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 15.16.5. Monoamine Oxidase Inhibitors (MAOIs) 15.16.6. Benzodiazepines 15.16.7. Atypical Antipsychotics 15.16.8. Anticonvulsants 15.16.9. Beta-Blockers 15.16.10. Others 15.17. Mexico Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 15.17.1. Electroconvulsive Therapy (ECT) 15.17.2. Cognitive Behavior Therapy (CBT) 15.17.3. Psychotherapy 15.17.4. Deep Brain Stimulation 15.17.5. Transcranial Magnetic Stimulation (TMS) 15.17.6. Cranial electrotherapy stimulation (CES) 15.18. Rest of South America Anxiety Disorder and Depression Treatment Market Forecast, by Application 15.18.1. Phobia 15.18.2. Major Depressive Disorder 15.18.3. Obsessive Compulsive Disorder (OCD) 15.18.4. Post-traumatic stress disorder 15.18.5. Others 15.19. Rest of South America Anxiety Disorder and Depression Treatment Market Forecast, by Drug class 15.19.1. selective Serotonin Reuptake Inhibitors (SSRIs) 15.19.2. Antidepressant Drugs 15.19.3. Tricyclic Antidepressants (TCAs) 15.19.4. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) 15.19.5. Monoamine Oxidase Inhibitors (MAOIs) 15.19.6. Benzodiazepines 15.19.7. Atypical Antipsychotics 15.19.8. Anticonvulsants 15.19.9. Beta-Blockers 15.19.10. Others 15.20. Rest of South America Anxiety Disorder and Depression Treatment Market Forecast, by Therapies 15.20.1. Electroconvulsive Therapy (ECT) 15.20.2. Cognitive Behavior Therapy (CBT) 15.20.3. Psychotherapy 15.20.4. Deep Brain Stimulation 15.20.5. Transcranial Magnetic Stimulation (TMS) 15.20.6. Cranial electrotherapy stimulation (CES) 15.21. South America Anxiety Disorder and Depression Treatment Market Attractiveness Analysis 15.21.1. By Application 15.21.2. By Drug class 15.21.3. By Therapies 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Eli Lilly and Company, 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Eli Lilly and Company, 16.3.3. Forest Laboratories, Inc., 16.3.4. AstraZeneca PLC, 16.3.5. Sanofi-Aventis, 16.3.6. Merck & Co., Inc., 16.3.7. Pfizer, Inc., 16.3.8. GlaxoSmithKline plc. 16.3.9. Johnson & Johnson 16.3.10. H. Lund beck A/S, 16.3.11. Forest Laboratories, Inc., 16.3.12. Sanofi-Aventis 16.3.13. Novartis AG 16.3.14. Mylan N.V 16.3.15. Glenmark Life Sciences Limited 16.3.16. Lupin Limited 16.3.17. Amneal Pharmaceuticals Inc. 16.3.18. Sun Pharmaceutical Industries Ltd. 16.3.19. Sumitomo Dainippon Pharma Co. Ltd. 16.3.20. Intas Pharmaceuticals Ltd. 17. Primary Key Insights

About This Report

Report ID 39288
Category Healthcare
Published Date Dec 2019
Updated Date Aug 2022
Contact Us